Exosome Diagnostics Discovers World’s First Kidney Transplant Rejection Signature from a Simple Urine Test

ROTTERDAM, Netherlands–(BUSINESS WIRE)–Exosome Diagnostics, a developer of revolutionary biofluid-based
molecular diagnostics, in collaboration with Brigham and Women’s
Hospital, in Boston, Mass., presented initial discovery and validation
data for a kidney transplant rejection signature at the International
Society for Extracellular Vesicles (ISEV) Annual Meeting.
Patients with end stage renal disease (ESRD) usually undergo
transplantation, however as many as 20% of these patients develop acute
kidney rejection. Methods for monitoring clinical rejection includes an
increase in serum creatinine and urinary protein secretion. These
methods are not very accurate and may not reflect subclinical rejection.
Currently, the patients are often monitored by repeat biopsies that may
result in increased complications and cost.
“A need exists for a liquid biopsy diagnostic test that is non-invasive
and would allow for earlier diagnosis and treatment to minimize the
amount of immunosuppression and avoid the complications associated with
repeat biopsies,” said Jamil R. Azzi, MD, Director, Kidney
Transplantation Fellowship Program, Assistant Professor, Harvard Medical
School. “These data show that exosomes are a promising new platform for
biomarkers and can be used to monitor RNA and protein expression.”
“We are thrilled to see the result of this collaboration,” added Johan
Skog, PhD, Chief Scientific Officer of Exosome Diagnostics. “It is
another example of how exosome RNA can be used to detect and monitor
disease progression in a non-invasive way.”
“These data are one of many indications from which Exosome Diagnostics
has utilized the power of its platform to expand beyond indications in
oncology and develop diagnostic signatures that may be utilized in the
clinic, as well as in the company’s companion diagnostic programs with
external partners,” said John Boyce, President and CEO of Exosome
Diagnostics. “The company’s isolation methodology, cell-free DNA and
exosomal RNA in one step, analysis pipelines, and proprietary algorithms
in combination allow for the elucidation of liquid biopsy data and rapid
procurement of signatures.”
The potential of data presented at ISEV for a transplant rejection
signature provides additional rationale as to why Exosome Diagnostics
has been building the company around the best patented exosome isolation
technology and platform. The company’s exosomal RNA technology began in
cancer diagnostics, and may now hold promise in transplantation as well
as other initiatives in cardiovascular, neurodegenerative, and
inflammatory diseases. The sky is the limit, and patients worldwide will
someday reap the rewards.
The platform will allow Exosome Diagnostics to continue bringing the
best liquid biopsies to the clinic. The company has already launched
ExoDx^® Lung(ALK) in cancer diagnostics and we are
excited for the upcoming launch of ExoDx^®Prostate(IntelliScore)
from two biofluids, blood and urine.
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing
and commercializing revolutionary biofluid-based diagnostics to deliver
personalized precision healthcare that improves lives. The company’s
novel exosome-based technology platform, ExoLution^®, can
yield comprehensive and dynamic molecular insights to transform how
cancer and other serious diseases are detected, diagnosed, treated and
monitored. Visit www.exosomedx.com
to learn more.
ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome
Diagnostics and ExoLution are unregistered trademarks of Exosome
Diagnostics, Inc.